Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor

被引:0
|
作者
Darrin Morrissey
Joe O'Connell
Deirdre Lynch
Gerald C. O'Sullivan
Fergus Shanahan
J. Kevin Collins
机构
[1] Departments of Microbiology,
关键词
antisense treatment; human esophageal carcinoma cell lines; invasion; urokinase; urokinase receptor.;
D O I
10.1023/A:1026470417680
中图分类号
学科分类号
摘要
Early metastasis contributes to the very poor prognosis of esophageal carcinoma. The recent immunohistochemical finding that invasive esophageal carcinomas express elevated levels of urokinase (uPA) and urokinase receptor (uPA-R) in vivo suggest that the plasminogen activation system may contribute to metastasis in esophageal cancer. The aim of our study was to functionally investigate, at the molecular level, the relative contribution of uPA and uPA-R to the invasiveness of esophageal cancer cells in vitro. The three esophageal cancer cell lines, OC1-3, generated in our laboratory, were analyzed for uPA and uPA-R expression by RT-PCR, immunoenzymatic staining, and quantitative ELISA. Invasiveness of all cell lines was quantified as percentage cellular invasiveness in a standardized Matrigel in vitro assay. OC1 and OC3, which were found to coexpress both uPA and uPA-R, displayed stronger invasiveness (44% and 32.5% respectively) relative to OC2 (19%) which expressed uPA-R but was negative for uPA. Transfection of OC2 cells with the uPA cDNA resulted in two variants, OC2.uPA1 and OC2.uPA2, stably expressing functional uPA. Both transfectants exhibited enhanced invasiveness (60% and 50% respectively) relative to the parent uPA-negative OC2 cells (19%). Antisense oligonucleotide inhibition of either uPA or uPA-R expression resulted in a similar, marked reduction in invasiveness of esophageal tumor cells which normally coexpress both molecules (OC1, OC3 and the uPA-expressing OC2-transfectant clones). Neither antisense treatment altered the basal invasiveness of OC2, which expresses uPA-R but not uPA. In conclusion, coexpression of uPA with its receptor, uPA-R, is required for functional involvement of the urokinase system in invasion by esophageal carcinoma cells. Our results suggest that these synergistic mediators of invasiveness are quantitatively major contributors to the invasiveness of esophageal carcinoma.
引用
收藏
页码:87 / 95
页数:8
相关论文
共 50 条
  • [31] Targeting the Urokinase Plasminogen Activator Receptor (uPAR)/Urokinase Plasminogen Activator (uPA) System in Acute Myeloid Leukemia
    Mroz, Pawel
    Kosciuczuk, Ewa
    Mazer, Andrew
    Platanias, Leonidas
    LABORATORY INVESTIGATION, 2015, 95 : 366A - 366A
  • [32] The Urokinase Receptor Promotes Cancer Metastasis Independently of Urokinase-Type Plasminogen Activator in Mice
    Jo, Minji
    Takimoto, Shinako
    Montel, Valerie
    Gonias, Steven L.
    AMERICAN JOURNAL OF PATHOLOGY, 2009, 175 (01): : 190 - 200
  • [33] STUDIES ON FUNCTIONAL AND STRUCTURAL ROLE OF UROKINASE RECEPTOR AND OTHER COMPONENTS OF THE PLASMINOGEN ACTIVATION SYSTEM IN MALIGNANCY
    WEIDLE, UH
    WOLLISCH, E
    RONNE, E
    PLOUG, M
    BEHRENDT, N
    DEVRIES, TJ
    QUAX, PH
    VERHEIJEN, JH
    VANMUIJEN, GNP
    RUITER, DJ
    HOYERHANSEN, G
    DANO, K
    ANNALES DE BIOLOGIE CLINIQUE, 1994, 52 (11) : 775 - 782
  • [34] Inhibition of pericellular urokinase plasminogen activator activity and basement membrane cell invasion by novel small molecule urokinase
    Molloy, CJ
    Sharp, C
    Manthey, CL
    Zhou, Z
    Randle, T
    Green, D
    Hoffman, J
    Subasinghe, N
    Rudolph, J
    Wilson, K
    Deckman, I
    Bone, R
    Illig, C
    CLINICAL CANCER RESEARCH, 1999, 5 : 3740S - 3741S
  • [35] The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
    Foekens, JA
    Peters, HA
    Look, MP
    Portengen, H
    Schmitt, M
    Kramer, MD
    Brünner, N
    Jänicke, F
    Meijer-van Gelder, ME
    Henzen-Logmans, SC
    van Putten, WLJ
    Klijn, JGM
    CANCER RESEARCH, 2000, 60 (03) : 636 - 643
  • [36] Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer
    Foersti, A.
    Lei, H.
    Tavelin, B.
    Enquist, K.
    Palmqvist, R.
    Altieri, A.
    Hallmans, G.
    Hemminki, K.
    Lenner, P.
    ANNALS OF ONCOLOGY, 2007, 18 (12) : 1990 - 1994
  • [37] Inhibition of the tumor-associated urokinase-type plasminogen activation system:: Effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo
    Magdolen, V
    Krüger, A
    Sato, S
    Nagel, J
    Sperl, S
    Reuning, U
    Rettenberger, P
    Magdolen, U
    Schmitt, M
    MOLECULAR STAGING OF CANCER, 2003, 162 : 43 - 63
  • [38] Urokinase receptor urokinase system in U937 cells and mature monocytes
    Arefieva, E
    Volynskaya, E
    Baidun, L
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 59 - 59
  • [39] Identification of urokinase plasminogen activator (uPA) and urokinase plasminogen activator receptor (uPAR) as therapeutic targets for pancreatic cancer.
    Della Croce, K
    Han, H
    Beroza, P
    Bearss, DJ
    von Hoff, DD
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3668S - 3668S
  • [40] Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis
    Shariat, Shahrokh F.
    Roehrborn, Claus G.
    McConnell, John D.
    Park, Sangtae
    Alam, Nina
    Wheeler, Thomas M.
    Slawin, Kevin M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (04) : 349 - 355